Abstract
Studies on human erythropoietin (EPO) demonstrated that there is a direct relationship between the sialic acid-containing carbohydrate content of the molecule and its serum half-life and in vivo biological activity, but an inverse relationship with its receptor-binding affinity. These observations led to the hypothesis that increasing the carbohydrate content, beyond that found naturally, would lead to a molecule with enhanced biological activity. Hyperglycosylated recombinant human EPO (rHuEPO) analogues were developed to test this hypothesis. Darbepoetin alfa (novel erythropoiesis stimulating protein, NESP, ARANESPTM, Amgen Inc, Thousand Oaks, CA), which was engineered to contain 5 N-linked carbohydrate chains (two more than rHuEPO), has been evaluated in preclinical animal studies. Due to its increased sialic acid-containing carbohydrate content, NESP is biochemically distinct from rHuEPO, having an increased molecular weight and greater negative charge. Compared with rHuEPO, it has an approximate 3-fold longer serum half-life, greater in vivo potency, and can be administered less frequently to obtain the same biological response. NESP is currently being evaluated in human clinical trials for treatment of anaemia and reduction in its incidence. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Boissel JP and Bunn HF (1990) Erythropoietin structure-function relationships. In: Dainiak N, Cronkite EP, McCaffrey R, Shadduck RK, eds The Biology of Hematopoiesis. pp 227–232, NewYork: Wiley-Liss
Broudy VC, Lin N, Egrie J, de Haeen C, Weiss T, Papayannopoulou T and Adamson JW (1988) Identification of the receptor for erythropoietin on human and murine erythroleukemia cells and modulation by phorbol ester and dimethyl sulfoxide. Proc Natl Acad Sci USA 85: 6513–6517
Browne JK, Cohen AM, Egrie JC, Lai PH, Lin FK, Strickland T, Watson E and Stebbing N (1986) Erythropoietin: gene cloning, protein structure, and biological properties. Cold Spring Harb Symp Quant Biol 51: 693–702
Cazzola M, Mercuriali F and Brugnara C (1997) Use of recombinant human erythropoietin outside the setting of uremia. Blood 89: 4248–4267
Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J and Harvey TS (1998) NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nature Struct Biol 5: 861–866
Cumming DA (1991) Glycosylation of recombinant protein therapeutics: control and functional implications. Glycobiology 1: 115–130
D’Andrea AD, Lodish HF and Wong GG (1989) Expression cloning of the murine erythropoietin receptor. Cell 57: 277–285
Davis JM, Arakawa T, Strickland TW and Yphantis DA (1987) Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26: 2633–2638
Delorme E, Lorenzini T, Giffin J, Martin F, Jacobsen F, Boone T and Elliott S (1992) Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 31: 9871–9876
Dordal MS, Wang FF and Goldwasser E (1985) The role of carbohydrate in erythropoietin action. Endocrinology 116: 2293–2299
Dube S, Fisher JW and Powell JS (1988) Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Biol Chem 263: 17516–17521
Egrie JC, Strickland TW, Lane J, Aoki K, Cohen AM, Smalling R, Trail G, Lin FK, Browne JK and Hines DK (1986) Characterization and biological effects of recombinant human erythropoietin. Immunobiology 172: 213–224
Egrie JC, Grant JR, Gillies DK, Aoki KH and Strickland TW (1993) The role of carbohydrate on the biological activity of erythropoietin. Glycoconjugate J 10: 263
Egrie JC, Dwyer E, Lykos M, Hitz A and Browne JK (1997) Novel erythropoiesis stimulating protein (NESP) has a longer serum half-life and greater in vivo biological activity than recombinant human erythropoietin (rHuEPO). Blood 90: 56a (abstract 243)
Elliott SG, Lorenzini T, Strickland T, Delorme E and Egrie JC (2000) Rational design of novel erythropoiesis stimulating protein (ARANESP™): a super-sialated molecule with increased biological activity. Blood 96: 82a (abstract 352)
Eschbach JW, Egrie JC, Downing MR, Browne JK and Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73–78
Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE and Haley NR (1989) Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111: 992–1000
Evans RW, Rader B and Manninen DL (1990) The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 263: 825–830
Fukuda MN, Sasaki H, Lopez L and Fukuda M (1989) Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 73: 84–89
Goldwasser E, Kung CK and Eliason J (1974) On the mechanism of erythropoietin-induced differentiation. 13. The role of sialic acid in erythropoietin action. J Biol Chem 249: 4202–4206
Higuchi M, Oh-eda M, Kuboniwa H, Tomonoh K, Shimonaka Y and Ochi N (1992) Role of sugar chains in the expression of the biological activity of human erythropoietin. J Biol Chem 267: 7703–7709
Krantz SB (1991) Erythropoietin. Blood 77: 419–434
Lacombe C and Mayeux P (1998) Biology of erythropoietin. Haematologica 83: 724–732
Lai PH, Everett R, Wang FF, Arakawa T and Goldwasser E (1986) Structural characterization of human erythropoietin. J Biol Chem 261: 3116–3121
Lin FK (1987) The molecular biology of erythropoietin. Rich IN Molecular and cellular aspects of erythropoietin and erythropoiesis, 23–36
New York Springer Lodish HF, Hilton DJ, Klingmuller U, Watowich SS and Wu H (1995) The erythropoietin receptor: biogenesis, dimerization, and intracellular signal transduction. Cold Spring Harb Symp Quant Biol 60: 93–104
Lowry PH, Keighley G and Borsook H (1960) Inactivation of erythropoietin by neuraminidase and mild substitution reactions. Nature 185: 102–103
Lukowsky WA and Painter RH (1972) Studies on the role of sialic acid in the physical and biological properties of erythropoietin. Can J Biochem 50: 909–917
Macdougall IC on behalf of the ARANESP™ UK Study Group (1998) Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia. J Am Soc Nephrol 9: 258a–259a (abstract A1317)
Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J and Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10: 2392–2395
Markham A and Bryson HM (1995) Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 49: 232–254
Miyake T, Kung CK and Goldwasser E (1977) Purification of human erythropoietin. J Biol Chem 252: 5558–5564
Narhi LO, Arakawa T, Aoki KH, Elmore R, Rohde MF, Boone T and Strickland TW (1991) The effect of carbohydrate on the structure and stability of erythropoietin. J Biol Chem 266: 23022–23026
Recny MA, Scoble HA and Kim Y (1987) Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem 262: 17156–17163
Sasaki H, Bothner B, Dell A and Fukuda M (1987) Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 262: 12059–12076
Sasaki H, Ochi N, Dell A and Fukuda M (1988) Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. Biochemistry 27: 8618–8626
Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA and Wiley DC (1984) A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci USA 81: 1779–1783
Sowade B, Sowade O, Moecks J, Franke W and Warnke H (1998) The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med 1: 303–314
Spivak JL and Hogans BB (1989) The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 73: 90–99
Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J and Stroud RM (1998) Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395: 511–516
Takeuchi M, Takasaki S, Miyazaki H, Kato T, Hoshi S, Kochibe N and Kobata A (1988) Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J Biol Chem 263: 3657–3663
Tsuda E, Goto M, Murakami A, Akai K, Ueda M, Kawanishi G, Takahashi N, Sasaki R, Chiba H and Ishihara H (1988) Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins. Biochemistry 27: 5646–5654
Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR and Cotes PM (1986) Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175–1178
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Egrie, J., Browne, J. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84 (Suppl 1), 3–10 (2001). https://doi.org/10.1054/bjoc.2001.1746
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1746
Keywords
This article is cited by
-
Development and validation of a method for analyzing the sialylated glycopeptides of recombinant erythropoietin in urine using LC–HRMS
Scientific Reports (2023)
-
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–2022
BioDrugs (2023)
-
Cyclic thrombocytopenia related to erythropoietin-dependent anti-platelet anti-GPIV/IIIb antibody in hemodialysis
Journal of Nephrology (2022)
-
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial
International Journal of Hematology (2022)
-
Production of galactosylated complex-type N-glycans in glycoengineered Saccharomyces cerevisiae
Applied Microbiology and Biotechnology (2022)
